Two notable pharma updates are summarized. Amgen reported positive topline Phase 3 results for TEPEZZA (teprotumumab-trbw) delivered subcutaneously via an on-body injector in moderate-to-severe active thyroid eye disease (TED).
The OBI-administered trial met its primary endpoint, showing a 77% proptosis response during the 24-week placebo-controlled period (TEPEZZA OBI 76.7% vs 19.6% placebo; p-value not provided in the extract). Secondary endpoints showed statistically significant improvements in overall responder rate, Clinical Activity Score (0–1), diplopia measures, and GO-QoL appearance subscale; GO-QoL visual functioning subscale showed a non-significant numerical trend favoring TEPEZZA OBI.
Safety mirroring the IV profile was noted, with mild-to-moderate injection-site reactions and common adverse events including muscle spasms, tinnitus, weight decrease, ear discomfort, nausea, and diarrhea. No treatment interruptions due to injection-site reactions were reported.
Separately, Regeneron announced FDA Priority Review of a Biologics License Application for garetosmab in adults with fibrodysplasia ossificans progressiva (FOP). Garetosmab, a monoclonal antibody targeting Activin A, is supported by the OPTIMA Phase 3 trial, showing large reductions in both new HO lesions and total lesion volume at 56 weeks for two dosing regimens.
The study’s primary endpoint was met, showing a 77% proptosis response rate during the 24-week placebo-controlled period.
This compares to a 19.6% response with placebo, with a statistical and clinical meaning assigned to the difference.
Additional secondary endpoints demonstrated improvements in overall responder rate,Clinical Activity Score (CAS) 0–1 achievement, diplopia measures (response, complete responder, and ordinal categories), and a favorable change in the Graves’ Ophthalmopathy Quality of Life (GO-QoL) appearance subscale at week 24.
A numerical, non-significant trend favored TEPEZZA OBI for GO-QoL visual functioning.
Full results will be shared at a forthcoming medical congress.
Safety outcomes were broadly consistent with the known IV TEPEZZA profile; injection-site reactions occurred in some patients but did not lead to treatment interruption or discontinuation.
The most common adverse events (≥10%) included muscle spasms, tinnitus, weight loss, ear discomfort, nausea, and diarrhea.
The sponsor framed the data as extending best-in-class efficacy and delivering IV-level results through a more convenient, subcutaneous route that could broaden patient access.
The FDA issued Priority Review, with an anticipated decision date in August 2026.
The BLA is supported by data from the Phase 3 OPTIMA trial, where both 3 mg/kg and 10 mg/kg doses of garetosmab significantly reduced the number and volume of new HO lesions at 56 weeks versus placebo.
Specific efficacy signals included a 94% reduction in new HO lesions for the 3 mg/kg cohort and a 90% reduction for the 10 mg/kg cohort in the primary endpoint analysis, with post-hoc analyses showing more than a 99% reduction in mean total lesion volume for both doses.
Serious treatment-emergent adverse events were infrequent across groups (1 in 3 mg/kg, 2 in 10 mg/kg, 2 in placebo).
The most common adverse reactions (≥30%) included epistaxis, increased hair growth, abscess, and acne.
Garetosmab has received Fast Track designation and Orphan Drug designation in the U.S., with Orphan designation in the EU, and additional regulatory submissions planned globally.
The safety and efficacy profile remains investigational and not yet approved by any regulatory authority.
The data reinforce TEPEZZA’s activity across multiple clinical endpoints relevant to TED, including proptosis and functional ocular symptom measures, as well as patient-reported QoL metrics.
Interviews with clinical experts emphasize the potential for expanded accessibility and continuity of care given a subcutaneous formulation, while acknowledging the need for full data presentation at scientific meetings.
If approved, this agent would add a mechanism-guided approach targeting Activin A to a rare disease with significant functional limitation and high care needs.
The regulatory path remains contingent on the FDA’s final assessment of the BLA, with an August 2026 decision window and internationally anticipated submissions.
The primary endpoint focused on proptosis response within a 24-week, placebo-controlled period, accompanied by multiple secondary efficacy measures and a safety profile aligned with IV TEPEZZA experiences.
The trial also reported safety outcomes including the occurrence of serious adverse events and common adverse reactions.
The available safety profile mirrors known TEPEZZA IV data, but comprehensive comparative safety in a subcutaneous context awaits fuller data disclosure.
Although OPTIMA provides robust efficacy signals, post-approval safety monitoring and real-world performance remain to be determined.
Clinicians may anticipate a shift in workflow associated with subcutaneous self-administration or assisted administration via an on-body device, subject to safety and labeling considerations.
Given the rarity and progressive nature of FOP, the regulatory decision will likely influence future development strategies for Activin A–modulating therapies and the broader field of rare skeletal disorders.
The emphasis on delivery modality and targeted mechanisms underscores a trend toward patient-centered design in rare disease therapeutics.
Readers should await the forthcoming congress presentations and published full-text reports for comprehensive interpretation, including the magnitude of effect across all endpoints and a fuller safety taxonomy.
While these developments suggest meaningful advances, definitive conclusions await complete data disclosure and regulatory determinations.
The source notes explicitly that “inclusion in Pharma Fridays does not suggest endorsement,” and emphasizes that safety and efficacy remain investigational until authorities authorize final use.